Nine Masts Capital’s Starling Oncology STLN Stock Holding History

Nine Masts Capital’s Portfolio STLN Stock Details STLN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	–	Sell	-14,018	Closed	-$43K	–	292
2026 Q1	$43K	Buy	+14,018	New	+$43K	0.01%	165

Other funds holding STLN

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Deerfield Management New York $9.59B AUM 113.36% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

JAIC

Josh Arnold Investment Consultant Edina, Minnesota $159M AUM 142.62% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Wexford Capital West Palm Beach, Florida $782M AUM 62.56% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Nuveen Charlotte, North Carolina $419B AUM 43.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Nine Masts Capital's STLN Position: Q2 2026 in Review

Nine Masts Capital sold out of Starling Oncology (STLN) in Q2 2026, closing a stake of 14,018 shares — an estimated $43K sold.

Nine Masts Capital first reported a position in STLN in Q1 2026 and held it in 1 quarter. The position peaked at $43K in Q1 2026. 119 funds tracked by Wall St. Rank hold STLN as of Q2 2026.

Nine Masts Capital reported no remaining Starling Oncology position as of Q2 2026 after selling out during the quarter.
Nine Masts Capital sold 14,018 Starling Oncology shares in Q2 2026, an estimated $43K.
Nine Masts Capital first reported a position in Starling Oncology in Q1 2026 and held it in 1 quarter.
Nine Masts Capital's Starling Oncology position peaked at $43K in Q1 2026.
119 funds tracked by Wall St. Rank held Starling Oncology as of Q2 2026.

Based on Nine Masts Capital's 13F filing for Q2 2026, filed 7 Aug 2026.